US8022082 — Method for the administration of an anticholinergic by inhalation
Method of Use · Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2026-01-19 · 0y expired
What this patent protects
This patent protects a method for administering an inhalable powder containing tiotropium, specifically through an inhaler with a certain flow resistance.
USPTO Abstract
An inhalation kit comprising: (a) an inhaler displaying a flow resistance of about 0.01 to 0.1 â{square root over (kPa)} min/L; and (b) an inhalable powder comprising tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 to 500 μm, and a method of administering an inhalable powder containing tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 μm to 500 μm, the method comprising actuating an inhaler a flow resistance of about 0.01 to 0.1 â{square root over (kPa)} min/L containing the inhalable powder.
Drugs covered by this patent
- Spiriva (TIOTROPIUM BROMIDE) · Boehringer Ingelheim
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1186 |
— | Spiriva |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.